Phase II study of fulvestrant (Faslodex®) in castration resistant prostate cancer

Prostate

Volumn 68, Issue 13, 2008, Pages 1461-1466

  Chadha, Manpreet K ^a   Ashraf, Umeer ^b   Lawrence, David ^a   Tian, Lili ^a   Levine, Ellis ^a   Silliman, Carrie ^a   Escott, Paul ^c   Payne, Valencia ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Palmetto Health   (United States)

Author keywords

Castration; Estrogen antagonist; Fulvestrant; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; DOCETAXEL; DUTASTERIDE; FULVESTRANT; GEFITINIB; GLUCOCORTICOID; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR;

ADULT; AGED; ANAMNESIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFORMED CONSENT; INJECTION SITE PAIN; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; CASTRATION; DOSE RESPONSE; DRUG ANTAGONISM; INTRAMUSCULAR DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PROSTATE TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASTRATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; HUMANS; INJECTIONS, INTRAMUSCULAR; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 50949093030     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20813     Document Type: Article

References (40)

1. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22(14):2927-2941.
2. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin 2002;20(19):3972-3982.
3. Oefelein MG, Ricchiuti VS, Conrad PW, et al. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 2002;60(1):120-124.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
5. Chang SS, Benson MC, Campbell SC, et al. Society of urologic oncology position statement: Redefining the management of hormone-refractory prostate carcinoma. Cancer 103(1):11-21.
6. Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005;173(6):1947-1952.
7. Ross RW, Kantoff PW. Hormone-refractory prostate cancer: Choosing the appropriate treatment option. Oncology (Williston Park) 2007;21(2):185-193.
8. Shelley M, Harrison C, Coles B. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;18(4):CD005247.
9. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
10. Kin-Mang L, LaSpina M II, John L, Shuk-Mei H. Expression of estrogen receptor (ER)-a and ER-b in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-3182.
11. Arnold JT, Liu X, Allen JD, et al. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 2007;67(11):1152-1162.
12. Signoretti S, Loda M. Estrogen receptor b in prostate cancer brake pedal or accelerator? Am J Path 2001;159(1):13-16.
13. Pasquali D, Rossi V, Esposito D, et al. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 2001;86(5):2051-2055.
14. Horvath LG, Henshall SM, Head DR, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001;61(14):5331-5335.
15. Fixemer T, Remberger K, Bonkoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003;54(2):79-87.
16. Ye Q, Cinar B, Edlund M, Chung LW, Zhau HE. Inhibition of growth and cell cycle arrest of ARCaP human prostate cancer cells by ectopic expression of ER-alpha. Mol Cell Biochem 2001;228(1-2):105-110.
17. Byar DP, Coyle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-170.
18. Smith DC, Redman BG, Flaherty LE, et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52(2):257-260.
19. Robertson CN, Robertson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88(13):908-917.
20. Kim IY, Seong DH, Kim BC, et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res 2002;62(13):3649-3653.
21. Kim IY, Kim BC, Seong DH, et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002;62(18):5365-5369.
22. Shazer RL, Jain A, Galkin AV, et al. Raloxifene, an oestrogen-receptor- beta-targeted therapy, inhibits androgen-independent prostate cancer growth: Results from preclinical studies and a pilot phase II clinical trial. BJU Int 2006;97(4):691-697.
23. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002;62(5):1370-1376.
24. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex®): Development of a novel, "pure' anti-estrogen. Cancer 2000;89:817-825.
25. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-3873.
26. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037-4041.
27. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-1388.
28. Preisler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-α. Am J Physiol Endocrinol Metab 2002;282:E891-E898.
29. Leung YK, Gao Y, Lau KM, Zhang X, Ho SM. ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia 2006;8(4):242-249.
30. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60(12):3175-3182.
31. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
32. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
33. Kepner JL, Chang MN. On the maximum total sample size of a group sequential test about binomial proportions. Stat Probability Lett 2003;62:87-92.
34. Kepner JL, Chang MN. Samples of exact k-stage group sequential designs for Phase II and Pilot Studies. Control Clin Trials 2004;25:326-333.
35. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
36. Robertson JF, Erikstein B, Osborne KC, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004;43(8):529-538.
37. Robertson JFR. Fulvestrant (Faslodex) - How to make a good drug better. The Oncologist 2007;12:774-784.
38. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-3467.
39. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-6746.
40. Gutteridge E, Robertson JFR, Cheung KL, et al. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer - Final results. Breast Cancer Res Treat 2004;88(Suppl 1):S177.